Multiple studies have indicated that upregulation of SNHG6 is associated with poor prognosis, lymph node metastasis and TNM stage in patients with ESCC,6 CRC8 and HCC,11 but its expression has been shown to be downregulated in CRC.17 SNHG6 is also upregulated in lung adenocarcinoma (LUAD) and positively associated with TNM stage and tumor size in LUAD patients.18 However, the prognostic significance of SNHG6 in patients with NSCLC is unclear. Here, SNHG6 is linked to esophageal squamous cell carcinoma.